These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 21615434)
1. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study. Lee TW; Singh R; Fedorak RN Aliment Pharmacol Ther; 2011 Jul; 34(2):181-7. PubMed ID: 21615434 [TBL] [Abstract][Full Text] [Related]
2. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study. Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522 [TBL] [Abstract][Full Text] [Related]
7. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632 [TBL] [Abstract][Full Text] [Related]
8. Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease. Ma D; Wong W; Aviado J; Rodriguez C; Wu H Am J Gastroenterol; 2019 Feb; 114(2):352-354. PubMed ID: 30333541 [TBL] [Abstract][Full Text] [Related]
9. Infliximab therapy in children and adolescents with inflammatory bowel disease. Veres G; Baldassano RN; Mamula P Drugs; 2007; 67(12):1703-23. PubMed ID: 17683171 [TBL] [Abstract][Full Text] [Related]
10. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort. Bálint A; Rutka M; Végh Z; Kürti Z; Gecse KB; Banai J; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Patai Á; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Bor R; Milassin Á; Fábián A; Nagy F; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Lakatos PL; Molnár T; Farkas K Expert Opin Drug Saf; 2017 Aug; 16(8):885-890. PubMed ID: 28504555 [TBL] [Abstract][Full Text] [Related]
11. Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study. Babouri A; Roblin X; Filippi J; Hébuterne X; Bigard MA; Peyrin-Biroulet L J Crohns Colitis; 2014 Feb; 8(2):161-5. PubMed ID: 23994253 [TBL] [Abstract][Full Text] [Related]
13. A nurse-led accelerated procedure for infliximab infusion is well tolerated and effective in patients with inflammatory bowel disease. Michielan A; Martinato M; Favarin A; Zanotto V; Caccaro R; Caruso A; Sturniolo GC; D'Incà R Dig Liver Dis; 2015 May; 47(5):372-7. PubMed ID: 25708258 [TBL] [Abstract][Full Text] [Related]
14. The safety of infliximab infusions in the community setting. Ducharme J; Pelletier C; Zacharias R Can J Gastroenterol; 2010 May; 24(5):307-11. PubMed ID: 20485705 [TBL] [Abstract][Full Text] [Related]
15. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre. Wee JS; Petrof G; Jackson K; Barker JN; Smith CH Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545 [TBL] [Abstract][Full Text] [Related]
16. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Jacobstein DA; Markowitz JE; Kirschner BS; Ferry G; Cohen SA; Gold BD; Winter HS; Heyman MB; Baldassano RN Inflamm Bowel Dis; 2005 May; 11(5):442-6. PubMed ID: 15867583 [TBL] [Abstract][Full Text] [Related]
17. Infliximab infusion time in patients with inflammatory bowel diseases: is longer really safer? Belhassan M; Zeitoun JD; Lefevre JH; Charachon A; Amiot A; Le Baleur Y; Sobhani I; Delchier JC Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):189-92. PubMed ID: 23246140 [TBL] [Abstract][Full Text] [Related]
18. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability. Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395 [TBL] [Abstract][Full Text] [Related]
19. The incidence and management of infusion reactions to infliximab: a large center experience. Cheifetz A; Smedley M; Martin S; Reiter M; Leone G; Mayer L; Plevy S Am J Gastroenterol; 2003 Jun; 98(6):1315-24. PubMed ID: 12818276 [TBL] [Abstract][Full Text] [Related]